Stocks · News reference
RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $290
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
Johnson & Johnson is expected to report Q3 2026 earnings of $2.90 per share (up 3.6% YoY) and revenues of $25.37 billion (up 5.8% YoY) on October 13. However, the company's Earnings ESP is -0.01% with a Zacks Rank #3, making it difficult to predict an earnings beat. While JNJ has beaten consensus estimates in all four of the last quarters, recent analyst revisions have turned slightly bearish, suggesting the stock may not be a compelling earnings-beat candidate.
9 Of 11 Sectors Rise In Tuesday Trading As Defensives Lead
Nine of 11 sectors are higher in Tuesday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Utilities well ahead of the next group.